Recon: Merck’s endometrial cancer treatment falters in study; Novo signs $600M deal with Metaphore to develop new obesity drugs
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States